promazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2284 58-40-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • promazine
  • prazin
  • prazine
  • romtiazin
  • promazine hydrochloride
  • promazine HCl
A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.
  • Molecular weight: 284.42
  • Formula: C17H20N2S
  • CLOGP: 4.60
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 6.48
  • ALOGS: -4.14
  • ROTB: 4
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O
0.10 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.02 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 2 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 50.23 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 16.25 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 8.10 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 14 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.11 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 7.90 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 2.343 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.558 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 27.353 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 167.109 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 8.900 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 13.380 % High 1
herg hERG pIC50 5.772 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 22.439 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 38.371 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 10.750 % High 1
kinase-safety-class ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,CHEK1,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PAK4,PDK2,PDK4,PDPK1,PIK3CB,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK 51
kinase-selectivity-class PDK4 1
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.475 High 1
mh-clint Mouse hepatocyte intrinsic clearance 314.775 High 1
mppb Mouse plasma protein binding (% unbound) 14.750 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.690 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 1 Moderate 0.78
pppb Pig plasma protein binding (% unbound) 29.660 % High 1
rh-clint Rat hepatocyte intrinsic clearance 306.902 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 47.640 % High 1
rppb Rat plasma protein binding (% unbound) 12.450 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 909.913 uM High 1

Approvals:

DateAgencyCompanyOrphan
April 13, 1956 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 923.15 66.99 193 2096 24451 90601707
Drug abuse 490.05 66.99 148 2141 82199 90543959
Intentional self-injury 301.41 66.99 81 2208 29253 90596905
Intentional overdose 180.69 66.99 73 2216 93761 90532397
Suicide attempt 160.16 66.99 63 2226 75336 90550822
Electrocardiogram QT prolonged 107.83 66.99 47 2242 72409 90553749
Drug interaction 78.84 66.99 61 2228 276392 90349766
Bradyphrenia 68.54 66.99 19 2270 7593 90618565
Coma 67.33 66.99 34 2255 72598 90553560

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 291.70 36.95 76 1921 13126 42606212
Suicide attempt 159.44 36.95 65 1932 46035 42573303
Intentional overdose 142.63 36.95 62 1935 51394 42567944
Intentional self-injury 130.37 36.95 42 1955 15160 42604178
Drug abuse 127.42 36.95 72 1925 104699 42514639
Somnolence 102.81 36.95 70 1927 141035 42478303
Coma 49.65 36.95 31 1966 53523 42565815
Drug interaction 45.57 36.95 59 1938 266940 42352398
Renal ischaemia 43.51 36.95 11 1986 1659 42617679
Bradyphrenia 42.84 36.95 14 1983 5248 42614090
Electrocardiogram QT prolonged 37.62 36.95 25 1972 47920 42571418

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Sopor 1162.83 42.86 270 3936 36276 110548817
Drug abuse 544.73 42.86 216 3990 177195 110407898
Intentional self-injury 424.18 42.86 122 4084 37307 110547786
Intentional overdose 220.09 42.86 105 4101 132396 110452697
Suicide attempt 215.68 42.86 96 4110 103298 110481795
Electrocardiogram QT prolonged 135.39 42.86 71 4135 108889 110476204
Drug interaction 117.56 42.86 118 4088 500065 110085028
Bradyphrenia 109.60 42.86 33 4173 11695 110573398
Coma 103.11 42.86 61 4145 117808 110467285
Somnolence 98.39 42.86 85 4121 297364 110287729
Alcohol interaction 89.38 42.86 22 4184 3672 110581421
Intentional product misuse 79.25 42.86 54 4152 132850 110452243
Overdose 75.58 42.86 66 4140 233728 110351365
Neuroleptic malignant syndrome 68.83 42.86 31 4175 34028 110551065
Hypotension 63.20 42.86 88 4118 523761 110061332
Inappropriate antidiuretic hormone secretion 47.56 42.86 24 4182 33827 110551266
Drug reaction with eosinophilia and systemic symptoms 43.37 42.86 31 4175 82064 110503029
Tachycardia 43.23 42.86 48 4158 226597 110358496

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AA03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with aliphatic side-chain
MeSH PA D000932 Antiemetics
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014150 Antipsychotic Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018492 Dopamine Antagonists
CHEBI has role CHEBI:35476 antipsychotic agent
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drug
CHEBI has role CHEBI:37955 H<small><sub>1</sub></small>-receptor antagonist
CHEBI has role CHEBI:48279 serotonergic antagonist
CHEBI has role CHEBI:48561 dopaminergic antagonist
CHEBI has role CHEBI:48876 muscarinic antagonist
CHEBI has role CHEBI:50919 antiemetic
CHEBI has role CHEBI:76779 EC 3.4.21.26 (prolyl oligopeptidase) inhibitor

Related Drugs by ATC class:

N05AA Phenothiazines with aliphatic side-chain 6 drugs
acepromazinechlorproethazinechlorpromazinecyamemazinelevomepromazinetriflupromazine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dermatographic urticaria indication 7632005 DOID:743
Nausea and vomiting indication 16932000
Angioedema indication 41291007 DOID:1558
General anesthesia indication 50697003
Disruptive behavior disorder indication 54319003
Schizophrenia indication 58214004 DOID:5419
Allergic rhinitis indication 61582004
Nasal discharge indication 64531003
Nasal congestion indication 68235000
Psychotic disorder indication 69322001
Sneezing indication 76067001
Urticaria indication 126485001
Bipolar affective disorder, current episode manic indication 191618007
Acute intermittent porphyria indication 234422006 DOID:3890
Itching of skin indication 418363000
Vomiting indication 422400008
Nausea indication 422587007
Allergic conjunctivitis indication 473460002 DOID:11204
Pre-Op Apprehension indication
Tetanus Adjunct Treatment indication
Intractable Hiccups indication
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Tranquilization Indication
Cats Adjunctive therapy for tetanus Indication
Cats Antiemetic prior to worming Indication
Cats Preanesthesia Indication
Cats Minor operative procedures in conjunction with local anesthesia Indication
Dogs Tranquilization Indication
Dogs Adjunctive therapy for tetanus Indication
Dogs Antiemetic prior to worming Indication
Dogs Prevent motion sickness Indication
Dogs Preanesthesia Indication
Dogs Minor operative procedures in conjunction with local anesthesia Indication
Horses Tranquilization Indication
Horses Adjunctive therapy for tetanus Indication
Horses Preanesthesia Indication
Horses Minor operative procedures in conjunction with local anesthesia Indication

🐶 Veterinary products

ProductApplicantIngredients
Promazine HCl Injectable Zoetis Inc. 1
Promazine Granules Zoetis Inc. 1
Ketaset Plus Zoetis Inc. 3
Tranquazine Injection Bimeda Animal Health Limited 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.04 Basic
pKa2 3.55 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 6.70 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.80 WOMBAT-PK CHEMBL
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 6.94 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 7.34 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 7.89 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.53 DRUG MATRIX
5-hydroxytryptamine receptor 2B GPCR Ki 6.66 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 7.28 DRUG MATRIX
5-hydroxytryptamine receptor 6 GPCR Ki 6.90 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Ki 8.23 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.50 WOMBAT-PK
D(3) dopamine receptor GPCR ANTAGONIST Ki 6.80 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.70 WOMBAT-PK
Histamine H2 receptor GPCR Ki 5.55 DRUG MATRIX
Muscarinic acetylcholine receptor M1 GPCR Ki 6.83 WOMBAT-PK
Muscarinic acetylcholine receptor M2 GPCR Ki 6.41 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 7.06 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 7.38 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 7.34 DRUG MATRIX
Aldehyde oxidase Enzyme IC50 5.80 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.43 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.52 DRUG MATRIX
Alpha-1D adrenergic receptor GPCR Ki 8.43 DRUG MATRIX
Major prion protein Surface antigen EC50 5.30 CHEMBL
Solute carrier family 22 member 1 Transporter IC50 4.76 CHEMBL
Lysine-specific histone demethylase 1A Enzyme IC50 5.33 CHEMBL
Sodium channel alpha subunits; brain (Types I, II, III) Ion channel IC50 5.27 CHEMBL
FAD-linked sulfhydryl oxidase ALR Enzyme AC50 5.89 CHEMBL
D(1A) dopamine receptor GPCR Ki 5.91 DRUG MATRIX
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 Enzyme IC50 5.42 CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.90 DRUG MATRIX
Trypanothione reductase Enzyme Ki 4.23 CHEMBL
Alpha-1B adrenergic receptor GPCR Ki 8.34 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 5.81 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 8.03 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 5.29 CHEMBL
Histamine H1 receptor GPCR IC50 5.90 CHEMBL
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 4.95 CHEMBL
Dopamine receptor GPCR IC50 6.89 CHEMBL
Dopamine receptor GPCR IC50 5.98 CHEMBL

External reference:

IDSource
4019909 VUID
N0000147994 NUI
D00797 KEGG_DRUG
4018021 VANDF
4019909 VANDF
C0033399 UMLSCUI
CHEBI:8459 CHEBI
P2Z PDB_CHEM_ID
CHEMBL564 ChEMBL_ID
CHEMBL1200469 ChEMBL_ID
DB00420 DRUGBANK_ID
D011395 MESH_DESCRIPTOR_UI
4926 PUBCHEM_CID
7281 IUPHAR_LIGAND_ID
600 INN_ID
53-60-1 SECONDARY_CAS_RN
O9M39HTM5W UNII
142444 RXNORM
2128 MMSL
5366 MMSL
7219 MMSL
d00356 MMSL
001471 NDDF
004588 NDDF
372741002 SNOMEDCT_US
44658005 SNOMEDCT_US
79135001 SNOMEDCT_US
O9M39HTM5W INXIGHT DRUGS

Pharmaceutical products:

None